Senate Democrats Accuse GOP of Orchestrating Multibillion Pharma Bailout

In a letter addressed to President Donald Trump, the Democratic lawmakers highlighted that the GOP package stalls critical price negotiations that were previously scheduled to begin next year. The senators contend there is no policy justification for the delay, asserting the move functions solely as a financial windfall for drug manufacturers at the expense of seniors facing rising costs for life-saving care. The controversy is compounded by the bill’s broader fiscal strategy, which offsets these industry gains by cutting approximately $1 trillion from Medicaid over the next decade. This reduction threatens to strip health coverage from millions of Americans, a contradiction the senators labeled a cruel irony. They further criticized the administration for abandoning the negotiation framework established by the 2022 Inflation Reduction Act. Instead of pursuing domestic price controls, the administration has pressured companies to raise prices internationally—a strategy described by critics as a performative gesture. Steve Knievel of Public Citizen echoed these concerns, dismissing the President's recent correspondence with drug companies as ineffective. Knievel argued that meaningful change requires legislative action to lower costs domestically, rather than rhetoric. Meanwhile, the administration continues to face scrutiny over mathematically improbable promises to reduce drug costs by as much as 1,200%, a figure that would effectively require companies to pay patients for accepting medication.